Embera NeuroTherapeutics is a pharmaceutical company focused on developing innovative treatments for addiction. Their mission is to create therapies that target specific brain functions to reduce cravings and prevent relapse in individuals addicted to substances such as cocaine, nicotine, and methamphetamine. Embera operates primarily in the United States, aiming to address significant unmet needs in addiction treatment through advanced research and development.

The company has achieved notable milestones, including the completion of Series B financing and securing grants to advance their lead product, EMB-, into Phase clinical studies for cocaine use disorder and smoking cessation. These achievements underscore Embera's commitment to pioneering effective addiction treatments and highlight their potential impact on public health.